Oral Cancer - Pipeline Review, H2 2012


#135225

71pages

Global Markets Direct

$ 2000

In Stock


Oral Cancer Pipeline Review, H2 2012

Global Markets Directs, 'Oral Cancer Pipeline Review, H2 2012', provides an overview of the Oral Cancer therapeutic pipeline. This report provides information on the therapeutic development for Oral Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Oral Cancer. 'Oral Cancer Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Oral Cancer.
  • A review of the Oral Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. 
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Oral Cancer pipeline on the basis of route of administration and molecule type.
  • Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Oral Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. 
  • Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Oral Cancer pipeline depth and focus of Oral Cancer therapeutics. 
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Oral Cancer Therapeutic Products under Development, Key Players in Oral Cancer Therapeutics, Oral Cancer Pipeline Overview, Oral Cancer Pipeline, Oral Cancer Pipeline Assessment
Table of Contents

Table of Contents 2

List of Tables 6
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Oral Cancer Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Oral Cancer 9
Oral Cancer Therapeutics under Development by Companies 11
Oral Cancer Therapeutics under Investigation by Universities/Institutes 12
Late Stage Products 15
Comparative Analysis 15
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Pre-Clinical Stage Products 18
Comparative Analysis 18
Oral Cancer Therapeutics Products under Development by Companies 19
Oral Cancer Therapeutics Products under Investigation by Universities/Institutes 20
Companies Involved in Oral Cancer Therapeutics Development 22
CEL-SCI Corporation 22
NexMed, Inc. 23
Oral Cancer Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Combination Products 25
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
HPPH - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Tarceva - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Avandia - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Actos - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Fludarabine + Radiation Therapy - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Survivin-Derived Peptide Vaccine - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Cetuximab + Cisplatin + Radiation Therapy - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 39
Cisplatin + Cytochlor + Tetrahydrouridine + Radiation Therapy - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Docetaxel + Cisplatin + 5-Fluorouracil - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Filgrastim + Palifermin + Cyclophosphamide + Etoposide + Ifosfamide - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 44
Erlotinib Hydrochloride + Radiation Therapy - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 46
Cisplatin + Paclitaxel + Radiation Therapy - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Lapatinib Ditosylate + Capecitabine - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 49
Taxotere + Cisplatin + 5-FU - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 51
Erbitux + Radiation Therapy - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Curcumin - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Docetaxel + Nedaplatin - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Multikine + Cyclophosphamide + Indomethacin + Zinc - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 56
Multikine + Cisplatin - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 58
Paclitaxel - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
ZD6474 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Erlotinib Hydrochloride + Linsitinib - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Erlotinib Hydrochloride - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Linsitinib - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Oral Cancer Therapeutics Drug Profile Updates 67
Oral Cancer Therapeutics Discontinued Products 68
Oral Cancer Therapeutics - Dormant Products 69

Appendix 70
Methodology 70
Coverage 70
Secondary Research 70
Primary Research 70
Expert Panel Validation 70
Contact Us 71
Disclaimer 71

Number of Products Under Development for Oral Cancer, H2 2012 9
Products under Development for Oral Cancer Comparative Analysis, H2 2012 10
Number of Products under Development by Companies, H2 2012 11
Number of Products under Investigation by Universities/Institutes, H2 2012 13
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 14
Comparative Analysis by Late Stage Development, H2 2012 15
Comparative Analysis by Mid Clinical Stage Development, H2 2012 16
Comparative Analysis by Early Clinical Stage Development, H2 2012 17
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 18
Products under Development by Companies, H2 2012 19
Products under Investigation by Universities/Institutes, H2 2012 20
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 21
CEL-SCI Corporation, H2 2012 22
NexMed, Inc., H2 2012 23
Assessment by Monotherapy Products, H2 2012 24
Assessment by Combination Products, H2 2012 25
Assessment by Stage and Route of Administration, H2 2012 27
Assessment by Stage and Molecule Type, H2 2012 29
Oral Cancer Therapeutics Drug Profile Updates 67
Oral Cancer Therapeutics Discontinued Products 68
Oral Cancer Therapeutics Dormant Products 69
Number of Products under Development for Oral Cancer, H2 2012 9
Products under Development for Oral Cancer - Comparative Analysis, H2 2012 10
Products under Development by Companies, H2 2012 11
Products under Investigation by Universities/Institutes, H2 2012 12
Late Stage Products, H2 2012 15
Mid Clinical Stage Products, H2 2012 16
Early Clinical Stage Products, H2 2012 17
Pre-Clinical Stage Products, H2 2012 18
Assessment by Monotherapy Products, H2 2012 24
Assessment by Combination Products, H2 2012 25
Assessment by Route of Administration, H2 2012 26
Assessment by Stage and Route of Administration, H2 2012 27
Assessment by Molecule Type, H2 2012 28
Assessment by Stage and Molecule Type, H2 2012 29